Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Jul;71(7):3775-81.
doi: 10.1128/IAI.71.7.3775-3781.2003.

Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine

Affiliations

Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine

Elisabeth Wedege et al. Infect Immun. 2003 Jul.

Abstract

Antibody specificities of pre- and postvaccination serum samples from 40 (53%) teenagers who received three doses of the Norwegian Neisseria meningitidis serogroup B vaccine (B:15:P1.7,16) during a previous trial in Iceland (Perkins et al., J. Infect. Dis. 177:683-691, 1998) were analyzed with serum bactericidal activity (SBA) and immunoblotting assays with reference and isogenic meningococcal H44/76 vaccine strains. The H44/76 variants demonstrated significant vaccine-induced SBA to P1.7,16 PorA and Opc but not to PorB, Opa5.5, and a heterologous PorA protein. On blots, immunoglobulin G levels to all these proteins increased significantly after vaccination. Measurement of SBA to the two main variable regions (P1.7 and P1.16) on the P1.7,16 PorA with PorA deletion mutants revealed significantly higher activity to the P1.7,- and P1.-,16 mutants compared to the P1.7,16 strain, indicating exposure of new accessible epitopes. Only 12 (30%) serum samples showed distinct decreases with these or the P1.-,- mutant, with most samples containing SBA to the P1.7 and P1.16 combination. In contrast, P1.16-specific antibodies were mainly found on blots. Thirteen of the vaccinees (32.5%) were carriers of meningococci at the time of the third dose, of whom four (30.8%) harbored strains of the ET-5 complex. Carriage of P1.15 strains was generally reflected in > or =4-fold increases in SBA and distinct immunoglobulin G binding to the P1.19,15 PorA on blots. Although vaccination did not elicit bactericidal activity to the serotype 15 PorB, most carriers of serotype 15 strains showed > or =4-fold increases in SBA to this antigen.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Bactericidal activity (mean log2 titers) against PorA of paired serum samples from 40 volunteers measured with isogenic PorA deletion mutants of H44/76. Compared with the P1.7,16 strain, titers against the P1.7,− (P = 0.003) and P1.−,16 (P = 0.021) strains were significantly higher, that for the PorA strain was significantly lower (P = 0.001), and no difference was found for the P1.−,− strain (P = 0.30).

Similar articles

Cited by

References

    1. Bash, M. C., F. Lynn, N. F. Concepcion, J. W. Tappero, G. M. Carlone, and C. E. Frasch. 2000. Genetic and immunological characterization of a novel serotype 4,15 strain of Neisseria meningitidis. FEMS Immunol. Med. Microbiol. 29:169-176. - PubMed
    1. Bjune, G., E. A. Høiby, J. K. Grønnesby, O. Arnesen, J. H. Fredriksen, A. Halstensen, E. Holten, A.-K. Lindbak, H. Nøkleby, E. Rosenqvist, L. K. Solberg, O. Closs, J. Eng, L. O. Frøholm, A. Lystad, L. S. Bakketeig, and B. Hareide. 1991. Effect of an outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096. - PubMed
    1. Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martinez, J. Arthur, P. Underwood, W. Silva, E. Moran, W. Hankins, J. Gilly, J. Mays, and the Chilean National Committee for Meningococcal Disease. 1995. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 13:821-829. - PubMed
    1. Caugant, D. A., P. Bol, E. A. Høiby, H. C. Zanen, and L. O. Frøholm. 1990. Clones of serogroup B Neisseria meningitidis causing systemic disease in the Netherlands 1958 through 1986. J. Infect. Dis. 162:867-874. - PubMed
    1. Delvig, A. A., E. Wedege, D. A. Caugant, R. Dalseg, J. Kolberg, A. Achtman, and E. Rosenqvist. 1995. A linear B-cell epitope on the class 3 outer-membrane protein of Neisseria meningitidis recognized after vaccination with the Norwegian group B outer-membrane vesicle vaccine. Microbiology 141:1593-1600. - PubMed

LinkOut - more resources